Print

AVEG 022

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox Alvac-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) May 01, 1995
ALVAC-HIV MN120TMG strain (vCP205) Canarypox Env gp120, TM gp41, gag, protease B MN/LAI
ALVAC-HIV MN120TMG strain (vCP205) Viral Vector - Pox
USA 76
NCT00001055
https://clinicaltrials.gov/show/NCT00001055